All categories
Science8 feeds
BioPharm International articles(biopharminternational.com)
<![CDATA[The BioPharm Brief: Deals, Data, and a $2 Billion Bet]]><![CDATA[Novo Nordisk Licenses Hengrui's Once-Weekly Oral GLP-1/GIP Dual Agonist HRS-1596 in Deal Worth Up to $2.6 Billion]]><![CDATA[iRegene's NouvSight001 Cleared for US and China RP Trials]]><![CDATA[uniQure's AMT-130 Shows Continued Slowing of Huntington's Disease at 48 Months, Though Primary Endpoint Misses Significance]]><![CDATA[AstraZeneca Invests $2 Billion in Summit's Ivonescimab ADC Combo]]><![CDATA[Building a BsAb CMC Playbook: Decision Frameworks, Risks, and Readiness]]><![CDATA[BioPharm International® Formulation Advances eBook September 2026 ]]>
Biotech / Medtech Archives | citybiz(citybiz.co)
Encision Raises $80,000 From Directors to Support Working CapitalRecent Patent and Court Developments in the U.S. and Europe Reinforce Danone’s Patent Position as Global Commercialization of Akkermansia MucT® ExpandsLifeCare Home Health & Hospice Names Nasser Khan President and COOInspiren Raises $70 Million Series C at $500 Million-Plus ValuationCerenome Secures Up to $20 Million to Scale CNSide DiagnosticsRide Therapeutics Secures Up to $7.3 Million From Cystic Fibrosis FoundationSCYNEXIS Appoints Sanjay Subramanian CFO as Biotech Advances Rare Disease Pipeline
Autism Target Discovered in Endothelial Cells in Genetic Deletion Mouse ModelDesigning Peptide Screens to Generate Knowledge, Not Just HitsMRSA Exploits Kidney’s Inner Environment to Persist and SpreadGenome-Wide Analysis Identifies BACH2 as Potential Fetal Hemoglobin Activation TargetAdvancing Brain Organoids from Research Models to Scalable PlatformsMicrobiome Patterns Vary Among Individuals with Different Cancer Types and Onset AgeAI and Proteomics Accelerate VAV1 Molecular Glue Discovery
Podcast: Why HPC is Absolutely Ready for the CloudIndustry Leaders on the Promise & Peril of NSCITim Carroll Joins Cycle Computing, Discusses HPC Cloud FutureUpdate on the HPCG BenchmarkDr. Lorena Barba Talks “Women Who CUDA”Virtual Observatories for Big Scientific DataReal World Performance Gains with CUDA 6
Gene therapy restores immune function to infants with SCID-X1 (X-linked severe combined immunodeficiency)Gene therapy company buyouts are making the newsTargeting solid tumors with natural killer (NK) cellsNobel Prize in Medicine for discovery of cancer immunotherapy via checkpoint inhibitionAlnylam’s patisiran, the first ever FDA- and European Commission-approved RNAi therapeuticNewLink Genetics—new organizational and clinical trial strategy for development of its cancer immunotherapy drug indoximodMIT study finds that the probability of clinical trial success is nearly 40% higher than previously thought
Viscosity Convergence Analysis for Deep Q-Networks
On the Effectiveness of the z-Transform Method in Quadratic Optimization
Adaptive Algorithms for Infinitely Many-Armed Bandits: A Unified Framework
OptunaHub: A Platform for Black-Box Optimization
Differentially Private Synthetic Data Generation for Relational Databases
Statistical Learning Theory for Neural Operators
From Zipf's Law to Neural Scaling through Heaps' Law and Hilberg's Hypothesis
Biotech IPOs Roar Back, With Nvidia-Backed Iambic Next in LineLife Biosciences Gets $80M as Cellular Rejuvenation Enters the ClinicGenerare Raises €20M to Explore Uncharacterized Chemical Space from Microbial DNACould Anthropic Disrupt the Techbio Companies Built for Pharma/Biotech?Big Pharma Is Betting On LLMs and Agents. What Would Count As Success?Is the Future of AI Drug Discovery Hybrid?Three AI Drug Discovery Startups Raise $526 Million in Two Days
Leading CDMO to attend CPHI Milan 2026 in ItalyEASD 2026: CagriSema weight loss holds at submaximal doses in REDEFINE-1 analysisAtossa plans shareholder stake in potential PRV proceedsOBIO marks $704m funding milestone for Canadian health tech venturesKyowa Kirin, Knight agree Latin American distribution deal for mogamulizumab EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2DNovo outlays $2.6bn in Hengrui deal to bolster oral obesity pipeline